Treatment of Orthostatic Hypotension in Autonomic Failure
Public ClinicalTrials.gov record NCT00223691. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation and Treatment of Autonomic Failure.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
Study identification
- NCT ID
- NCT00223691
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 389 participants
Conditions and interventions
Conditions
Interventions
- Atomoxetine Drug
- Acarbose Drug
- Pyridostigmine Bromide Drug
- Yohimbine Drug
- Midodrine HCl Drug
- placebo Drug
- Modafinil Drug
- Octreotide Drug
- water intake Other
- Diphenhydramine Hydrochloride Drug
- Ranitidine HCL Drug
- Tranylcypromine Drug
- Ergotamine/ Caffeine Drug
- Celecoxib Drug
- Pseudoephedrine Drug
- Methylphenidate Drug
- Indomethacin Drug
- Ibuprofen Drug
- Oxymetazoline 0.05% nasal solution Drug
- Bovril Dietary Supplement
- Acetazolamide Drug
- Rivastigmine tartrate Drug
- Carbidopa/levodopa Drug
- Inflatable abdominal binder Device
- inflatable abdominal binder (sham) Device
Drug · Other · Dietary Supplement + 1 more
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2002
- Primary completion
- Dec 31, 2016
- Completion
- Dec 31, 2016
- Last update posted
- Jan 17, 2017
2002 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00223691, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2017 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00223691 live on ClinicalTrials.gov.